Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119252 | 0.90 | PDE5A (0.62) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5120089 | 0.89 | PDE5A (0.61) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5129219 | 0.88 | PDE5A (0.60) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5121474 | 0.87 | PDE5A (0.59) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5115075 | 0.86 | PDE5A (0.47) | PDE5APDE3BPDE3AKCNN3MEN1 | |
| SCHEMBL5122505 | 0.86 | PDE5A (0.45) | PDE5APDE3BPDE3AKCNN3MEN1 | |
| SCHEMBL7619727 | 0.85 | PDE5A (0.64) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5122046 | 0.85 | PDE5A (0.67) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL5118528 | 0.83 | PDE5A (0.43) | PDE5APDE3BPDE3AKCNN3MEN1 | |
| SCHEMBL5129589 | 0.83 | PDE5A (0.54) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1875023-A | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2006-12-06 | — | — | CN | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PDE5A 2002/4885TBXAS1 70/4885PDE3B 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.